VANCOUVER, Dec. 21, 2017 /CNW/ - PUF Ventures Inc. ("PUF" or the "Company") (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations ("ACMPR") license applicant, is pleased to announce that PUF Ventures Australia's ("PUFA") applications for medicinal cannabis licenses for its Northern Rivers Project in New South Wales, Australia, for both cultivation and production, cannabis research license and manufacturing license have been accepted by the Office of Drug Control (ODC). The applications have now progressed to the assessment phase, all associated fees have been paid. The Company will continue to provide updates as appropriate while it progresses through the process.
The Company would also like to announce that PUF Ventures Australia will begin operating under a new corporate name and will be known as Solaris Nutraceuticals Pty Ltd. (formerly "PUF Ventures Australia").
"The new name reflects our focus on distinct innovations to provide medicinal cannabis grown under the Northern Rivers sun in our proposed 1.2 million square foot Ultra-Clima glass house," Michael Horsfall, President and CEO, Solaris Nutraceuticals Pty Ltd. "In addition to our name change, you will see a fresh new look and feel to the corporate image of the company which reflects the innovation, quality and environmentally sustainable products to be developed in our glasshouse and manufacturing facilities."
MYM Nutraceuticals (CSE: MYM) and PUF Ventures Inc. (CSE: PUF) are co-owners in Solaris Nutraceuticals.
About Solaris Nutraceuticals
Solaris Nutraceuticals is an innovative medical technology company with headquarters in Sydney, Australia. It has proposed plans and applications with Office of Drug Control in Australia to build a 1.2 million square foot glass house with a medical research center and manufacturing facility in the Northern Rivers Region of New South Wales. Our corporate mission is to deliver an environmentally friendly, sun grown medicinal grade cannabis, develop medicines and treatments for pain management and other medical conditions, and produce specific plant based nutraceuticals. Our focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., Weed Points Loyalty Inc., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Currently, AAA Heidelberg has not received a license from Health Canada. PUF is publicly traded under the following symbols: CSE: PUF, Frankfurt: PU3 and OTCPK: PUFXF. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
SOURCE PUF Ventures
For further information: PUF Ventures Inc., E: email@example.com, T: (800) 783-6056; Solaris Nutraceuticals Pty Ltd., Michael Horsfall, President & CEO, E: firstname.lastname@example.org, T: +61 417 041 272